Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.448
+0.034 (8.12%)
At close: Mar 9, 2026, 4:00 PM EDT
0.423
-0.024 (-5.45%)
After-hours: Mar 9, 2026, 7:01 PM EDT
Company Description
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Outlook Therapeutics, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | May 13, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Robert Jahr |
Contact Details
Address: 111 S. Wood Avenue, Unit #100 Iselin, New Jersey 08830 United States | |
| Phone | 609 619 3990 |
| Website | outlooktherapeutics.com |
Stock Details
| Ticker Symbol | OTLK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001649989 |
| CUSIP Number | 69012T206 |
| ISIN Number | US69012T3059 |
| Employer ID | 38-3982704 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Charles Jahr | President, Chief Executive Officer and Director |
| Lawrence A. Kenyon CPA | EVice President, Chief Financial Officer, Treasurer, Secretary and Director |
| Joel Prieve | Senior Vice President of Licensing and M&A |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development and Regulatory Affairs |
| Jedd Comiskey | Senior Vice President - Head of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 10-Q | Quarterly Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 11, 2026 | 8-K | Current Report |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 26, 2026 | ARS | Filing |
| Jan 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 26, 2026 | DEF 14A | Other definitive proxy statements |
| Jan 2, 2026 | 8-K | Current Report |